FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug
Onlookers had been expecting a thumbs up for filgotinib. Now, that won't happen for at least another year.
Full Article
FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug
Motley Fool
0 shares
1 views
You might like
Related news coverage
Target, Momenta Pharmaceuticals rise; BioMarin, TJX fall
SeattlePI.com
NEW YORK (AP) — Stocks that moved heavily or traded substantially Wednesday:
Momenta Pharmaceuticals Inc., up $21.31..